Clearside Biomedical, which is developing a combination drug-device therapy for eye diseases, raised $50 million by offering 7.2 million shares at $7, as expected. The company revised the terms of the deal on Wednesday; it originally planned to raise $60 million by offering 4.0 million shares at a range of $14-16. Clearside Biomedical plans to list on the Nasdaq under the symbol CLSD. Cowen & Company and Stifel acted as lead managers on the deal.
